

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange  
Act of 1934

February 3, 2003

-----  
(Date of earliest event reported)

LABORATORY CORPORATION OF AMERICA HOLDINGS

-----  
(Exact name of registrant as specified in its charter)

DELAWARE	1-11353	13-3757370
-----	-----	-----
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification Number)

358 SOUTH MAIN STREET, BURLINGTON, NORTH CAROLINA 27215

-----  
(Address of principal executive offices)

336-229-1127

-----  
(Registrant's telephone number, including area code)

ITEM 9. Regulation FD Disclosure.

Laboratory Corporation of America -Registered Trademark-  
Holdings (LabCorp -Registered Trademark-)(NYSE:LH) announced  
that it has signed an expanded agreement with Aetna to provide  
clinical laboratory testing and certain additional services to the  
850,000 Commercial HMO and Quality Point-of-Service Aetna members  
in Texas. The agreement also continues to cover all of Aetna's other  
health care members, including, PPO and indemnity plans.

"This agreement is important to LabCorp because we are now a provider  
for all Aetna products in Texas," said Stevan R. Stark, executive  
vice president for sales and marketing at LabCorp. "Now, Aetna's  
participating physicians in Texas may send all their clinical  
laboratory work to LabCorp, giving those physicians who prefer using a  
single laboratory greater choice in selecting a full service laboratory  
provider. Continually expanding our relationships with large managed care  
providers is part of LabCorp's strategy to broaden access to its full  
menu of diagnostic testing services, including medically important  
genomic tests."

Each of the above forward-looking statements is subject to  
change based on various important factors, including without  
limitation, competitive actions in the marketplace and  
adverse actions of governmental and other third-party  
payors. Actual results could differ materially from those  
suggested by these forward-looking statements. Further  
information on potential factors that could affect LabCorp's  
financial results is included in the Company's Form 10-K  
for the year ended December 31, 2001 and subsequent SEC filings,

and will be available in the Form 10-K for the year ended December 31, 2002, when filed.

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LABORATORY CORPORATION OF AMERICA HOLDINGS

-----  
(Registrant)

By:/s/ BRADFORD T. SMITH

-----  
Bradford T. Smith  
Executive Vice President  
and Secretary

Date: February 3, 2003